Risk factors and outcomes of patients with ocular involvement of candidemia

Background Ocular involvement of candidemia can result in serious complications, including vision loss. This study investigated the risk factors for ocular involvement in patients with candidemia and the outcomes of treatment. Methods Episodes of candidemia in hospitalized adults who underwent ophthalmic examinations within 2 weeks of candidemia onset between January 2014 and May 2017 were retrospectively reviewed. Their demographic characteristics, antifungal treatments, and visual outcomes were evaluated. Results During the study period, 438 adults were diagnosed with candidemia, with 275 (62.8%) undergoing ophthalmic examinations within 2 weeks. Of these 275 patients, 59 (21.5%) had fundoscopic abnormalities suggestive of ocular involvement, including 51 with chorioretinitis and eight with Candida endophthalmitis. Eleven patients were symptomatic. Persistent candidemia (adjusted odd ratio [aOR], 2.55; 95% confidence interval [CI], 1.29–5.08; P = 0.01), neutropenia during the preceding 2 weeks (aOR, 2.92; 95% CI, 1.14–7.53; P = 0.03), and C. albicans infection (aOR, 2.15; 95% CI, 1.09–4.24; P = 0.03) were independently associated with ocular involvement. Among the 24 patients with neutropenia, 41.7% had ocular involvements at the initial examination. Ophthalmologic examination even before the neutrophil recovery was positive in one-third of neutropenic patients. Out of the 37 patients in whom ocular outcomes after 6 weeks were available, 35 patients showed favorable or stable fundoscopic findings. Two patients had decreased visual acuity despite the stable fundoscopic finding. Conclusion Neutropenia within two weeks of candidemia was a risk factor for ocular involvement. More than 80 percent of patients with ocular involvements were asymptomatic, emphasizing the importance of routine ophthalmic examinations. The median 6 weeks of systemic antifungal treatment resulted in favorable outcomes in 89.2% of patients.

[1]  H. Nakajima,et al.  Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with Candida bloodstream infection , 2018, Infection.

[2]  S. Sheu Endophthalmitis , 2017, Korean journal of ophthalmology : KJO.

[3]  J. Losa,et al.  No evidence of increased ocular involvement in candidemic patients initially treated with echinocandins. , 2017, Diagnostic microbiology and infectious disease.

[4]  J. Pemán,et al.  Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Durand Bacterial and Fungal Endophthalmitis , 2017, Clinical Microbiology Reviews.

[6]  J. Sobel,et al.  Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Edwards 258 – Candida Species , 2015 .

[8]  K. Nishimura,et al.  Intraocular Penetration of Intravenous Micafungin in Inflamed Human Eyes , 2013, Antimicrobial Agents and Chemotherapy.

[9]  M. Durand,et al.  Endophthalmitis , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  H. Flynn,et al.  Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes. , 2012, American journal of ophthalmology.

[11]  K. Ohkusu,et al.  Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis. , 2011, Journal of Ocular Pharmacology and Therapeutics.

[12]  J. Sobel,et al.  Ocular manifestations of candidemia. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Nucci Persistent Candidemia: Causes and Investigations , 2011 .

[14]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Falagas,et al.  Candida Albicans Versus Non-Albicans Intensive Care Unit-Acquired Bloodstream Infections: Differences in Risk Factors and Outcome , 2008, Anesthesia and analgesia.

[16]  Guangming Chen,et al.  Ocular distribution of intravenously administered micafungin in rabbits , 2008, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[17]  R. Khakoo,et al.  Candida Endophthalmitis: Focus on Current and Future Antifungal Treatment Options , 2007, Pharmacotherapy.

[18]  I. Çelik,et al.  The prevalence of bacteraemia-related retinal lesions in seriously ill patients. , 2006, The Journal of infection.

[19]  D. Andes,et al.  Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Bradley,et al.  Candida Glabrata Endophthalmitis Treated Successfully with Caspofungin , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Ph.D. Joseph Heitman M.D.,et al.  Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 2004, Mycopathologia.

[22]  John W. Miller,et al.  Retinal Lesions as Clues to Disseminated Bacterial and Candidal Infections: Frequency, Natural History, and Etiology , 2003, Medicine.

[23]  A. Eller,et al.  Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. , 1994, Ophthalmology.

[24]  R. Brooks,et al.  Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. , 1989, Archives of internal medicine.

[25]  L. Gentry,et al.  Endogenous endophthalmitis among patients with candidemia. , 1982, Ophthalmology.